Syros Pharmaceuticals, Inc.
SYRS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SYRS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2024.
Tracking 3 pipeline candidates for Syros Pharmaceuticals, Inc..
Run Syros Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Syros Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
8.9 months
OCF -$21M · Net income -$6M
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Short Interest
as of Apr 30, 2026- % of float
- 3.8%
- Days to cover
- 0.8
- Shares short
- 939,583
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SYRS short interestGovernance
Frequently asked questions
What is Syros Pharmaceuticals, Inc.'s lead drug candidate?
Syros Pharmaceuticals, Inc.'s most advanced tracked candidate is sy-2101 (Phase 1) for Acute promyelocytic leukemia (APL).
Who is the CEO of Syros Pharmaceuticals, Inc.?
Massachusetts April is the chief executive officer of Syros Pharmaceuticals, Inc. (SYRS).
Where is Syros Pharmaceuticals, Inc. headquartered?
Syros Pharmaceuticals, Inc. (SYRS) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Syros Pharmaceuticals, Inc. focus on?
Syros Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.